Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

NCT01300260 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL: LY2189265
DRUG: Placebo
DRUG: Insulin
DRUG: Glucose
DRUG: Glucagon

Sponsor

Eli Lilly and Company